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Low T3 has been associated with increased short-term mortality in intensive care unit and long-term mortality in cardiovascular
disease. The objective of this retrospective study is to investigate associations of thyroid hormone status with clinical severity
and outcome in acute ischemic stroke, and whether there is association between the pituitary axis abnormality and the
anterior/posterior circulation involvement. Patients with no history of thyroid abnormality who presented ﬁrst ever stroke were
studied. Total T3, T4, TSH levels, basic and clinical characteristics were collected and categorized. Neurological impairment was
assessed using NIHSS and modiﬁed Rankin Scale. Twenty-nine patients (61%) had T3 ≤ 75ng/dL. Low T3 group had signiﬁcant
higher NIHSS compared to normal T3 group. There was a signiﬁcant negative correlation between T3 levels and NIHSS scores
on admission. A signiﬁcantly smaller percentage of patients with low T3 showed favorable neurological function improvement by
both NIHSS and mRS measures compared to those with normal T3. There was no signiﬁcant diﬀerence for anterior or posterior
circulation involvement between low T3 and normal T3 groups. It is suggested that low T3 is associated with worse neurological
outcome. The severity of low T3 may be a predictor of functional improvement in acute ischemic stroke.
1.Introduction
Neuroendocrine proﬁle is signiﬁcantly altered in acute
ischemic stroke; low triiodothyronine (T3) has been asso-
ciated with increased short-term mortality in intensive care
unit patients and long-term mortality in patients with
heart disease [1–4]. This is known as nonthyroidal illness
syndrome (NTIS; or euthyroid sick syndrome or “low-T3
syndrome”). The most common hormone pattern in NTIS
is a decrease in T3 level with normal levels of thyroxine
(T4) and thyroid-stimulating hormone (TSH) [2, 5]. For
more severe illness, a decrease in T4 level occurs while the
TSH level does not show the expected pituitary thyroid axis
reactivity [2, 5].
In acute stroke, several factors such as C-reactive protein
(CRP), glucose levels on admission, ﬁbrinogen concentra-
tion, erythrocyte sedimentation rate, and leukocyte count
have been examined as prognostic factors for stroke outcome
and have been found to be associated with the increased
morbidity and mortality [6–8]. A reduction of serum T3
without elevation of thyroid-stimulating hormone appears
to be associated with the severity of stroke and worse clinical
outcome [9, 10]. Thus far, there were two studies that have
been published to address the importance of monitoring for
NTIS after acute stroke. Hama et al. from Japan reported
malnutrition and nonthyroidal illness syndrome after stroke
in2005[9];anotheronewasbyAlevizakietal.whodescribed
a low T3 levels is associated with outcome in acute stroke
patients from Greece in 2007 [10]. The probable correlation
between the decrease of thyroid hormones and the severity
of stroke as well as the poststroke recovery needs further
investigation. The objective of this pilot, retrospective study
is to investigate possible associations of thyroid hormone
status with clinical severity using National Institutes of
Health Stroke Scale (NIHSS) and outcome in patients
admitted for acute ischemic stroke, and whether there is
association between the pituitary axis abnormality and the
anterior or posterior circulation involvement.2 Stroke Research and Treatment
2.SubjectsandMethods
2.1. Study Population. Resident Research Committee of the
Jacobs Neurological Institute and Institutional Review Board
of University at Buﬀalo approved this study. All available
charts of 780 patients admitted with ischemic stroke at Mil-
lard Fillmore Gates Circle hospital in Buﬀalo, New York in
2009 were reviewed. Inclusion criteria: (1) any patients with
no history of thyroid abnormality who presented ﬁrst ever
stroke within 24h from symptoms’ onset; (2) patients with
thyroid functions including total T3, T4, and TSH obtained
in the morning following admission; (3) age 18 years and
older; (4) patients with available normal thyroid function
tests within one year prior to admission. Exclusion criteria:
(1) age less than 18; (2) patients with thyroidal dysfunction,
transient ischemic attacks, subarachnoid or intraparenchy-
mal hemorrhage, severe liver disease (e.g., liver cirrhosis),
and severe kidney disease (e.g., require artiﬁcial dialysis).
2.2. Data Collection and Source. Kaleida Health Infoclique
electronic record system and paper charts were utilized.
Head CT, MRI, MRA oﬃcial reports, physician dictations,
discharge and/or transfer summaries, and laboratory works
were carefully reviewed. Thyroid function was evaluated
by measuring serum total T3, T4, and TSH; T3, T4 were
measured by RIA (radioimmunoassay) and TSH by IRMA
(immunoradiometric assay) at Kaleida Health System. Nor-
mal range in our laboratory for T3 is 75–180ng/dL; normal
range for T4 is 5–11.5mcg/dl; normal range for TSH is
0.4–5μU/mL. Total T3, T4, and TSH levels obtained in the
morning following admission were collected.
Basic and clinical characteristics including demographic
data such as sex, age, cigarette smoking, concurrent illness,
medications (in the present study only ASA, plavix, or
coumadin were taken into account, these were all for
patients’ coronary artery diseases), and whether the stroke
involve the anterior or posterior circulation from brain
imaging were collected and categorized. We divided all
patients into 2 groups with one low-T3 group and other
normal-T3 group based on ﬁrst thyroid functions on day 1
after admission.
The severity distribution of NIHSS scores on admission
was divided into 3 categories, mild: NIHSS < 8; moderate:
NIHSS 8–14; severe: ≥14. Neurological impairment and
improvement were assessed using NIHSS, together with
modiﬁed Rankin Scale (mRS) [11, 12] from follow-up clinic
visits. NIHSS scores were repeated on patients’ ﬁrst outpa-
tient clinic follow-up; ΔNIHSS (improvement: a decrease of
NIHSS score) was then calculated from patient’s admission
NIHSS to assess functional improvement. Favorable out-
come is deﬁned as ΔNIHSS ≥ 2a n dm R S≤ 1[ 13]. The
ﬁrst clinic follow-up usually occurs 2–4 weeks after discharge
from hospital.
2.3. Statistical Analysis. Statistical analysis was performed
to compare patients with low T3 and normal T3 values.
Continuousdataarepresentedasmean(standarddeviation),
categorical data as percentages. Unpaired student t-test (for
continuous variables), chi-square (for categorical variables),
and correlative analysis will be used to determine if low
T3 levels are associated with acute ischemic stroke severity.
Diﬀerences were considered signiﬁcant at P<. 05. The
Statistical Package for Social Sciences (SPSS inc., version 16.0
for Windows) was used.
3. Results
Forty-seven patients with available laboratory data and rel-
atively complete neurological impairment documentations
met all inclusion criteria, 28 men, 19 women. Mean age was
67.4 ± 12.1. Twenty-nine patients (61%) had T3 ≤ 75ng/dL
and 18 patients had normal T3 values. The characteristics
of patients with low T3 and normal T3 are shown in
Table 1. Patients with low T3 had signiﬁcantly more severe
neurological impairment at presentation (P<. 05), higher
mean glucose levels on admission (P<. 05). Low-T3 group
had signiﬁcant higher NIHSS scores compared to normal-
T3 group (P<. 05). Patients’ distribution pattern of NIHSS
scores on admission showed that a much higher portion of
patients belonged to moderate-to-severe category (NIHSS:
8–14 or ≥14)forlow-T3groupwhilemajority ofpatients fell
into mild category for normal-T3 group (NIHSS < 8). There
was a trend of decreased T4 levels noted but did not yield a
signiﬁcant diﬀerence when compared to normal-T3 group;
but TSH levels showed no diﬀerence between low-T3 and
normal-T3 groups. In terms of cerebral blood supply terri-
tory aﬀected by stroke, there was no signiﬁcant diﬀerence for
anterior or posterior circulation involvement between low-
T3 and normal-T3 groups (P>. 05) (see Table 1).
From Figure 1, there was a signiﬁcant negative correla-
tion between T3 levels and NIHSS scores among all patients
(n = 47, r =− 0.758, r2 = 0.575, P<. 001, 95% Conﬁdence
Interval0.40to0.75).Thisimplies,afteracutestroke,thatthe
lower T3 values are, the worse neurological impairment will
be.
During patients’ ﬁrst outpatient clinic follow-up after
stroke, NIHSS scores were repeated along with mRS scores;
ΔNIHSS was calculated from patient’s admission NIHSS
scores to assess function improvement. We found that a
smaller percentage of patients with low T3 showed favorable
neurological function improvement by both NIHSS measure
(27.6% versus 66.7%, P<. 05) and mRS measure (31.0%
versus 55.6%, P<. 05) compared to those with normal T3;
in addition, median HIHSS and mRS scores tended to be
worse in low-T3 group when compared to normal-T3 group
on ﬁrst clinic follow-up visit (P<. 05; See Table 2).
4. Discussion
The major ﬁnding of this pilot, retrospective study showed
the association of T3 levels with short-term outcome after
the event of acute ischemic stroke. Our ﬁnding from the
present study has not been previously reported in the
United States using NIHSS measure. The most common
abnormality is low T3 among all four types of NTIS in
hospitalized especially those in intensive care units [14, 15].Stroke Research and Treatment 3
Table 1: Characteristics of acute ischemic stroke patients with low T3 and normal T3 values.
Low T3 group Normal T3 group
P-value (T3 ≤ 75ng/dL) (T3 > 75ng/dL)
n = 29 n = 18
Clinical variables
Age (years) 68.1 (±12.7) 66.8 (±11.5) NS
Sex (% male) 18 (62.1%) 11 (61.1%) NS
Smoking 9 (31.0%) 6 (33.3%) NS
Hypercholesterolemia 8 (27.6%) 5 (27.8%) NS
Coronary artery disease 5 (17.2%) 3 (16.7%) NS
Diabetes mellitus 9 (31.0%) 6 (33.3%) NS
Atrial ﬁbrillation 6 (20.1%) 4 (22.2%) NS
History of hypertension 19 (65.5%) 11 (61.1%) NS
BP on admission
Systolic BP (mmHg) 156.2 (±27.9) 150.2 (±29.5) NS
Diastolic BP (mmHg) 89.7 (±11.4) 87.8 (±14.2) NS
Baseline NIHSS scores 11.5 (±3.5) 6.6 (±4.3) <.05
Distribution of NIHSS scores
Mild (<8) 2 (6.9%) 15 (83.3%) <.01
Moderate (8–14) 17 (58.6%) 2 (11.1%) <.01
Severe (≥14) 10 (34.5%) 1 (5.6%) <.01
Laboratory variables
Anterior carotid artery territory 11 (37.9%) 7 (38.9%) NS
Posterior/basilar artery territory 6 (20.1%) 4 (22.2%) NS
Thyroid function tests
TSH (μU/mL) 1.24 (±1.19) 1.30 (±1.21) NS
T3 (ng/dL) 53.1 (±11.7) 109.5 (±21.6) <.01
T4 (ng/dL) 8.5 (±3.04) 9.2 (±2.6) NS
Initial WBC count 7.8 (±3.9) 7.3 (±2.5) NS
Initial hemoglobin 9.4 (±1.4) 9.1 (±1.8) NS
Glucose on admission (mmol/L) 135.6 (±56.8) 128.9 (±55.4) <.05
Medications
Antiplatelets/Anticoagulants 14 (48.3%) 9 (50%) NS
Numbers for nominal data indicate percentages in parentheses and for continuous data indicate mean ± standard deviation. Statistical signiﬁcance (P<. 05).
NS: no statistical signiﬁcance; BP: blood pressure; NIHSS: National Institutes of Health Stroke Scale; Baseline NIHSS scores: the initial scores on admission;
TSH: thyroid-stimulating hormone; T3: triiodothyronine; T4: thyroxine; Antiplatelets/Anticoagulants: ASA or Plavix or coumadin.
Low T3 has been reported in intracerebral hemorrhage
from either trauma or hemorrhagic infarct [16, 17]. It has
been generally accepted that low T3 accompanying severe
illness is considered as an adoptive response to stress to
spare energy [1–4, 14, 18] .W h e t h e ro rn o tt ot r e a tw i t h
thyroxin replacement is controversial [2, 5, 19–22], while
true hypothyroidism has been interestingly reported, that
a preexisting condition may actually be protective in acute
stroke [23, 24]. Like in other systemic severe illness, a reduc-
tion of serum T3 without elevation of thyroid-stimulating
hormone appears to be associated with the severity of stroke
and worse clinical outcome [9, 10, 25]. Possible mechanisms
include, but not limited to, the following: (1) peripheral
thyroid hormone metabolism changes due to alterations in
activity of the enzymes responsible for peripheral conversion
of T4 to T3 [26, 27]; (2) proinﬂammatory cytokine action
involvement; (3) a disturbed shift in the distribution of
thyroid hormones or an alteration in binding proteins [28,
29]; (4) excessive glucocortcoids releases in severe illness
which produce inhibition of activities from hypothalamic-
pituitary-thyroid axis and the conversion of T4 to T3 [30].
Our study showed that patients with low T3 were slightly
but not signiﬁcantly older than those with normal T3; but
Alevizaki et al.’s study showed signiﬁcant older age in low-T3
group [10]. This may have represented that elderly patients
usuallyhadalowbaselineofthyroidfunctionandtendednot
to fully compensate when such event occurs. Patients from
variable age group would have helped in the present study.
In the present study, low T3 appeared to be associated
with stroke severity and short-term outcome; furthermore,
there is a signiﬁcant negative correlation detected between
T3 levels and NIHSS scores on admission among all patients.
The latter is a novel ﬁnding which has not been reported
elsewhere, it indicates that a worse neurological impairment4 Stroke Research and Treatment
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Figure 1: Scatter plot graph shows the correlation between T3
valuesandNationalInstitutesofHealthStrokeScale(NIHSS)scores
on admission. Each circle represents a patient. r2 = 0.575, P<. 001,
95% Conﬁdence Interval 0.40 to 0.75.
Table 2: Stroke outcome measured by National Institutes of Health
Stroke Scale (NIHSS) and modiﬁed Rankin Scale (mRS).
Low T3 group Normal T3 group
(T3 ≤ 75ng/dL) (T3 > 75ng/dL)
n = 29 n = 18
The 1st day
Median value of NIHSS 11 (5∼19) 6 (2∼14)∗
The 1st clinic follow-up
Median value of NIHSS 9 (2∼17) 4 (0∼9)∗
Patients with any
improvement (ΔNIHSS ≥ 2) 8 (27.6%) 12 (66.7%)∗
Median value of mRS 3 (1∼5) 1 (0∼3)∗
Patients with favorable
outcome (mRS ≤ 1) 9 (31.0%) 10 (55.6%)∗
Numbers in parentheses for nominal data indicate percentages and for
continuous data indicate range of actual scores. ∗P<. 05 is compared
to low T3 group. The 1st day: on admission; The 1st clinic follow-up:
outpatient follow-up usually occurred 2–4 weeks after discharge; ΔNIHSS
≥ 2: improvement when scores decreased ≥2 compared to baseline.
is related to the degree of a decrease in T3 level, thus
T3 levels monitoring could potentially serve as an easy,
quick, and feasible prognostic parameter for clinicians in the
future if conﬁrmed by further studies [18]. Our ﬁnding is
consistent with Alevizaki et al. who stated that low-T3 is a
possible independent predictor for stroke outcome [10]. As
in several studies performed in intensive care units, acute
stroke patients with low T3 or the combination of T3 and
T4 appeared to be associated with worse prognosis [1–
4, 31]. Also, interestingly the alterations of T3 levels do not
appear to be related to the region (anterior versus posterior
circulation) aﬀected by stroke. This suggests that the alter-
ation is more related to a disturbance of thyroid hormone
metabolism rather than a blood supply abnormality induced
structuraldisturbanceofthehypothalamic-pituitary-thyroid
axis.
Limitations in the present study include selection biases,
small sample size, single baseline measurement of thyroid
function, lack of long-term follow-up, and interactions from
any drugs known to aﬀect thyroid functions which should all
be taken into account in the future study. Among the above
items, the confounding eﬀects from a few selection biases
such as whether patients had available laboratory results for
thyroid function tests and whether they presented to the
hospital deserve readers’ attention while reviewing or using
these data. Following studies are needed in the future: (1)
to monitor repeatedly TSH, T3, and T4 levels at speciﬁc
times relative to onset of stoke (i.e., at onset, 1st day, 1st
week, 1 month, 3 months); (2) to perform an adjusted
analysis such as logistic regression and Mantel-Haenszel test
to exam if T3 is indeed an independent predictor along
with other factors and whether the association between low
T3 syndrome and worse neurologic impairment is truly
signiﬁcant. Since there is still no conclusive answer as to
treatment of low T3 in the context of acute stroke, it would
be also conceivable to design a study on inﬂuential eﬀect
by providing proper thyroid hormone replacement. Some
studies reported advantage of brain “being preconditioned”
with hypothyroidism when a stroke occurs [10, 23, 24], this
result has led to an extensive discussion on the issue of
correction of low T3 levels after stroke [19, 32]; whereas
one animal study showed a neuroprotective eﬀects deﬁned
by reduction of infarct size and improvement of neurological
deﬁcit with administration of T3 [33].
In conclusion, NTIS is commonly seen after acute
ischemic stroke, and low T3 is associated with worse
neurological outcome. The severity of low T3 syndrome may
be a useful predictor of functional improvement in patients
with acute ischemic stroke. The study suggests that thyroid
hormone monitoring poststroke may be considered if the
present data are further conﬁrmed by future prospective
studies.
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